Therachon

Switzerland
Breíl, Grisons, Switzerland, 4051

Company profile

Therachon company profile

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

Business identity

Contact email
[email protected]
Phone number
+41798989209
Operating status
Closed
Company type
For Profit
Employee range
1-10 employees
Revenue range
$1M-$10M
Founded
2014-01-01, Year

Headquarters

Postal code
4051
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
3
Total equity funding
$100M
Last funding
Series B / $60M / 2018-08-09
Last equity funding
Series B / $60M
Investors
9
Lead investors
2
Founders
2
Articles
6
Closed on
2019-07-01
Exited on
2019-05-08

Founders and investors

Founders

Elvire GouzeLuca Santarelli

Lead investors

Novo HoldingsOrbiMed

Investors

BpifranceNew Enterprise AssociatesNovo HoldingsOrbiMedVersant Ventures